1. The FDA rejects about 25% of all positive recommendations.
Cangrelor may not be approved - "The benefit of cangrelor compared with clopidogrel is small, but the risk is smaller," from the review. The FDA is looking for significantly increased benefit, not just smaller risk.
2. Even if approved, the scope will be limited and the potential revenue stream negligible compared to Angiomax.
3. Biotech stocks usually drop upon approval and with the generic Angiomax coming out in June MDCO will have very little in it's arms chest.
4. Currently manipulated buy the pro's so they can sell high - and so should you.